drugset
drugset / Trial / NCT04710524

FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

NCT04710524 ↗

Phase 2 Unknown 60 enrolled Future Medicine
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Timeline

Start
2021-06-10
Primary completion
2023-05-31
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject FM101 Unknown 150 mg Oral
Subject FM101 Unknown 300 mg Oral

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis